Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

FRBRX Franklin Biotechnology Discovery R6

  • Fund
  • FRBRX
  • Price as of: Sep 17, 2019
  • $147.90 + $0.30 + 0.20%

FRBRX - Profile

Vitals

  • YTD Return 16.8%
  • 3 Yr Annualized Return 0.2%
  • 5 Yr Annualized Return -1.9%
  • Net Assets $1.07 B
  • Holdings in Top 10 42.4%

52 WEEK LOW AND HIGH

$147.90
$116.79
$168.45

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.70%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 28.62%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

STANDARD (TAXABLE)

$1,000,000

IRA

N/A

Fund Classification

PRIMARY CATEGORY

  • Fund Type Open End Mutual Fund
  • Investment Style Health

Distributions

  • YTD Total Return 16.8%
  • 3 Yr Annualized Total Return 2.6%
  • 5 Yr Annualized Total Return 2.0%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.30%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name Franklin Biotechnology Discovery Fund
  • Fund Family Name Franklin Templeton Investments
  • Inception Date May 01, 2013
  • Shares Outstanding 36212
  • Share Class Retirement
  • Currency USD
  • Domiciled Country United States
  • Manager Evan S. McCulloch

FRBRX - Performance

Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD 16.8% -1.5% 20.3% 8.11%
1 Yr -9.8% -28.1% 0.6% 47.71%
3 Yr 0.2%* -16.3% 15.1% 67.96%
5 Yr -1.9%* -11.6% 13.7% 51.04%
10 Yr N/A* -2.7% 14.1% N/A

* Annualized


Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2018 -18.2% -25.3% 21.5% 87.62%
2017 16.6% -10.8% 43.9% 49.51%
2016 -20.6% -31.6% 6.9% 77.00%
2015 -2.4% -20.4% 13.8% 56.12%
2014 29.3% -5.8% 31.5% 6.52%

Total Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD 16.8% -1.5% 20.3% 8.11%
1 Yr -9.8% -28.1% 1.3% 56.88%
3 Yr 2.6%* -16.3% 17.6% 61.17%
5 Yr 2.0%* -11.6% 17.1% 57.29%
10 Yr N/A* -2.7% 17.0% N/A

* Annualized


Total Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2018 -18.2% -25.3% 22.2% 88.57%
2017 19.3% -10.8% 45.8% 55.34%
2016 -16.8% -24.2% 8.7% 72.00%
2015 6.1% -16.6% 15.2% 51.02%
2014 34.3% -5.8% 36.7% 10.87%

NAV & Total Return History

FRBRX - Holdings

Concentration Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Assets 1.07 B 2.54 M 43.3 B 50.41%
Number of Holdings 82 30 390 57.02%
Net Assets in Top 10 485 M 604 K 17.9 B 51.24%
Weighting of Top 10 42.42% 23.0% 74.6% 37.19%

Top 10 Holdings

  1. Alexion Pharmaceuticals Inc 5.93%

  2. Gilead Sciences Inc 5.00%

  3. Vertex Pharmaceuticals Inc 4.87%

  4. Illumina Inc 4.55%

  5. Iovance Biotherapeutics Inc 4.28%

  6. GW Pharmaceuticals PLC ADR 4.22%

  7. Biogen Inc 3.94%

  8. Amgen Inc 3.40%

  9. Regeneron Pharmaceuticals Inc 3.16%

  10. Biomarin Pharmaceutical Inc 3.07%


Asset Allocation

Weighting Return Low Return High FRBRX % Rank
Stocks
90.83% 90.83% 99.99% 100.00%
Cash
8.99% 0.00% 8.99% 3.31%
Other
0.17% -4.27% 3.81% 21.49%
Preferred Stocks
0.00% 0.00% 2.47% 64.46%
Convertible Bonds
0.00% 0.00% 0.18% 61.98%
Bonds
0.00% 0.00% 0.20% 61.98%

Stock Sector Breakdown

Weighting Return Low Return High FRBRX % Rank
Healthcare
90.75% 63.42% 99.67% 92.56%
Energy
0.09% 0.00% 0.31% 4.13%
Utilities
0.00% 0.00% 0.00% 58.68%
Technology
0.00% 0.00% 22.28% 85.12%
Real Estate
0.00% 0.00% 1.71% 61.98%
Industrials
0.00% 0.00% 3.11% 71.07%
Financial Services
0.00% 0.00% 6.30% 66.94%
Communication Services
0.00% 0.00% 2.11% 59.50%
Consumer Defense
0.00% 0.00% 1.58% 65.29%
Consumer Cyclical
0.00% 0.00% 5.27% 64.46%
Basic Materials
0.00% 0.00% 1.58% 71.90%

Stock Geographic Breakdown

Weighting Return Low Return High FRBRX % Rank
US
82.36% 60.36% 99.29% 51.24%
Non US
8.47% 0.00% 39.22% 78.51%

FRBRX - Expenses

Operational Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.70% 0.10% 4.94% 95.41%
Management Fee 0.59% 0.09% 1.30% 20.66%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.01% 0.40% 71.43%

Sales Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 0.75% 2.00% N/A

Turnover Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 28.62% 0.00% 341.00% 24.11%

FRBRX - Distributions

Dividend Yield Analysis

FRBRX Category Low Category High FRBRX % Rank
Dividend Yield 0.00% 0.00% 1.23% 66.12%

Dividend Distribution Analysis

FRBRX Category Low Category High Category Mode
Dividend Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History


Net Income Ratio Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Income Ratio -0.30% -2.24% 1.48% 54.13%

Capital Gain Distribution Analysis

FRBRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

FRBRX - Managers

Evan S. McCulloch

Manager

Start Date

Tenure

Tenure Rank

Sep 15, 1997

21.97

22.0%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.


Steven Kornfeld

Manager

Start Date

Tenure

Tenure Rank

Sep 15, 2015

3.96

4.0%

Steven Kornfeld is VP, Research Analyst and Portfolio Manager with Franklin Equity Group. He specializes in research analysis of the pharmaceutical industry and is a member of the Franklin Core/Hybrid team. Prior to joining Franklin Templeton Investments in January 2001, Mr. Kornfeld most recently worked in private equity and previously as a sell-side research analyst where he specialized in covering emerging growth companies. He holds an MBA from Northwestern University and a bachelor’s degree from the Wharton School of Business at the University of Pennsylvania. He is a CFA®* Charterholder.


Wendy Lam

Manager

Start Date

Tenure

Tenure Rank

Sep 01, 2018

1.0

1.0%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co.


Tenure Analysis

Category Low

0.25

Category High

21.97

Category Average

9.56

Category Mode

19.35